Merck donates experimental malaria drug; AstraZeneca cuts 120 German jobs;

> Merck donated an investigational malaria drug to the Medicines for Malaria Venture for use in the developing world; under the agreement, MMV gets an exclusive, royalty-free license to develop the experimental med in malaria-endemic countries. Release

> AstraZeneca cut 120 jobs in Germany, or about 9 percent of its workforce of 1,300 there; the layoffs are part of AstraZeneca's previously announced job cuts. Report

> Medtronic said the number of deaths in which its fractured defibrillator wires may have been a "possible or likely contributing factor" has risen to 13. Report

> Drugmaker Warner Chilcott said the FDA will not delay rulings on two generic versions of the antibiotic Doryx. Report

> Abbott Laboratories accused rival Mylan Inc. of infringing two U.S. patents for the AIDS drug Kaletra. Report

> Teva Pharmaceutical Indusries won FDA approval for its version of the Medicis acne treatment Solodyn; the company has already started shipping the copycat meds despite ongoing patent litigation. Release

> Johnson & Johnson said it's going to test its Nevo stent against Abbott's popular Xience stent in a 2,000 patient, head-to-head trial. Report

> Federal health officials say a Johnson & Johnson drug helps prevent deadly blood clots in patients getting hip or knee replacement, but it also carries a risk of serious internal bleeding. Report

> Galashiels, Scotland-based ProStrakan said 2008 had been an "excellent year" for the company with product sales rising 32 percent and total revenue up 23 percent. Report

> Shares of Bayer AG were badly dented this morning after the FDA released staffers' critical remarks on Xarelto, a blood clot drug that will be reviewed by an expert committee on Thursday. Report

> Facing the need to raise new operating capital, Seattle-based Cell Therapeutics has hired on a financial adviser to counsel the company on its strategic alternatives. Report

> MannKind is determined to push into the commercial market for inhaled insulin--an ambitious move that Pfizer has already tried and failed. Report

> Shares of Switzerland's Cytos Biotechnology tanked after the developer said its high blood pressure vaccine failed a mid-stage trial. Cytos now says it will hand out pink slips to 42 percent of its work force--eliminating 57 jobs. The company's shares slid 33.5 percent on the news. Report

> With its R&D expenses shooting up and its lead program in clinical trials, South San Francisco-based Poniard Pharmaceuticals was handed a going-concern warning by its auditors. Poniard lost about $14 million in the fourth quarter, but says it has enough cash to fund operations at least into the first quarter of 2010. Report

> Roche has several big challenges waiting for it at Genentech. One example: Its $47 billion takeover of the biotech giant will make many of the California biotech's scientists rich. Very, very rich. Report

And Finally... Researchers have identified a master switch that might prevent cancer cells from metastasizing from a primary tumor to other organs. Release

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.